» Articles » PMID: 35145164

Tissue MiR-200c-3p and Circulating MiR-1290 As Potential Prognostic Biomarkers for Colorectal Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2022 Feb 11
PMID 35145164
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT)-related cancers generally elicit low immune responses. EMT is regulated by several microRNAs (miRNAs) in cancers. Thus, this study aimed to evaluate the prognostic potential of EMT-related miRNAs as biomarkers in colorectal cancer (CRC). Formalin-fixed paraffin-embedded tumor and normal tissue and plasma samples were obtained from 65 patients with pathologically confirmed CRC. In addition, plasma samples were obtained from 30 healthy volunteers. Immunohistochemical staining for E-cadherin, ZEB1, PD-1, PD-L1, CD3, CD4, CD8, Foxp3, and CD68 was conducted on tissue samples. Droplet digital polymerase chain reaction (ddPCR) analysis was performed to evaluate miR-21-5p, 34a-5p, 138-5p, 200a-3p, 200b-5p, 200c-3p, 630, 1246, and 1290 expression in tissue samples and miR-630, 1246, and 1290 expression in plasma samples. miR-21-5p, 34a-5p, 630, 1246, and 1290 expression was higher in tumor tissues than in normal tissues (P < 0.05). EMT was significantly associated with reduced tumor-infiltrating T cells. Moreover, miR-21-5p, miR-34a-5p, miR-200a-3p, and miR-200c-3p expression was negatively correlated with T cell density (P < 0.05). High tissue levels of miR-200c-3p were associated with poor overall survival (OS) (P < 0.001). CRC patients with the EMT phenotype had poor OS; however, PD-L1 positivity and abundant PD-1 positive immune cells were correlated with better OS (P < 0.05). miR-1246 and miR-1290 levels were significantly higher in the plasma of patients with CRC than in the plasma of healthy controls (P < 0.05). High plasma levels of miR-1290 were correlated with advanced stage and poor OS (P < 0.05). The tissue expression of miR-200c-3p and plasma levels of miR-1290 measured by ddPCR indicate their potential as prognostic biomarkers for CRC.

Citing Articles

MicroRNA-200c in Cancer Generation, Invasion, and Metastasis.

Guo H, Zhang N, Huang T, Shen N Int J Mol Sci. 2025; 26(2).

PMID: 39859424 PMC: 11766322. DOI: 10.3390/ijms26020710.


Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration.

Tveit Solheim E, Vestrheim Thomsen L, Bjorge L, Anandan S, Peter E, Desestret V Ann Clin Transl Neurol. 2024; 11(12):3255-3266.

PMID: 39473143 PMC: 11651201. DOI: 10.1002/acn3.52232.


Identification of common salivary miRNA in oral lichen planus and oral squamous cell carcinoma: systematic review and meta-analysis.

Koopaie M, Akhbari P, Fatahzadeh M, Kolahdooz S BMC Oral Health. 2024; 24(1):1177.

PMID: 39367474 PMC: 11452954. DOI: 10.1186/s12903-024-04986-0.


Gut microbiota and their derivatives in the progression of colorectal cancer: Mechanisms of action, genome and epigenome contributions.

Ahmad A, Mahmood N, Raza M, Mushtaq Z, Saeed F, Afzaal M Heliyon. 2024; 10(8):e29495.

PMID: 38655310 PMC: 11035079. DOI: 10.1016/j.heliyon.2024.e29495.


MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.

Zabeti Touchaei A, Vahidi S Cancer Cell Int. 2024; 24(1):102.

PMID: 38462628 PMC: 10926683. DOI: 10.1186/s12935-024-03293-6.


References
1.
Grenda A, Krawczyk P . New Dancing Couple: PD-L1 and MicroRNA. Scand J Immunol. 2017; 86(3):130-134. DOI: 10.1111/sji.12577. View

2.
Fakih M . Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015; 33(16):1809-24. DOI: 10.1200/JCO.2014.59.7633. View

3.
Meropol N, Schulman K . Cost of cancer care: issues and implications. J Clin Oncol. 2007; 25(2):180-6. DOI: 10.1200/JCO.2006.09.6081. View

4.
Loupakis F, Depetris I, Biason P, Intini R, Prete A, Leone F . Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist. 2020; 25(6):481-487. PMC: 7288636. DOI: 10.1634/theoncologist.2019-0611. View

5.
Mak M, Tong P, Diao L, Cardnell R, Gibbons D, William W . A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2015; 22(3):609-20. PMC: 4737991. DOI: 10.1158/1078-0432.CCR-15-0876. View